ImmuMed, Inc. is a development-stage biotechnology company founded to develop and market innovative therapeutic compounds that modify the human immune response to prevent or treat life-threatening disease. Currently, the Company focuses on commercializing polyclonal antibodies for adjuvant therapies, which is the administration of antibodies in conjunction with standard therapies in order to improve a patient’s outcome. In favor of pursuing curative products, many large pharmaceutical companies have abandoned the area of adjuvant antibodies, allowing smaller companies, such as ImmuMed, to capitalize on opportunities within this segment.